Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-09-09T19:59:59.000Z.
Consensus retrieved: 2026-09-10T02:29:41.670Z. This records retrieval, including cache reads, rather than vendor publication. A quote earlier than this retrieval cannot support current forward valuation.
Quote observation: 2026-09-09T19:59:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 500e3659350dc613f65989c8819860f7b015b190485c70a8fcc1b932ead8a96b
FORWARD PE RATIO
N/A
Agilent Technologies, Inc.
Market Cap
$40.89B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Agilent Technologies, Inc. (A) | $40.89B | N/A |
| IDEXX Laboratories, Inc. (IDXX)vs › | $40.64B | N/A |
| IQVIA Holdings Inc. (IQV)vs › | $42.30B | N/A |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.92B | N/A |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.52B | N/A |
| Humana Inc. (HUM)vs › | $48.03B | N/A |
| Alcon Inc. (ALC)vs › | $33.37B | N/A |
| Becton, Dickinson and Company (BDX)vs › | $49.54B | N/A |
| Edwards Lifesciences Corporation (EW)vs › | $49.62B | N/A |
| ResMed Inc. (RMD)vs › | $31.91B | N/A |
Trailing P/E
28.5
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $144.78 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-10-31 | $6.20 | $6.07 – $6.23 | 12 | 23.3x |
| 2027-10-31 | $6.75 | $6.57 – $7.03 | 13 | 21.4x |
| 2028-10-31 | $7.48 | $6.96 – $8.04 | 7 | 19.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
